Table 2 Adverse events in patients infused with CAR T-cell therapy.
Adverse event | Patients with active EMD | Patients without EMD | p Value |
|---|---|---|---|
CRS, n (%) | N = 47 | N = 105 | |
Any grade (1–5) | 38 (81) | 82 (78) | 0.7001 |
Grade 3–5 | 5 (11) | 3 (3) | 0.0471 |
ICANS, n (%) | N = 47 | N = 105 | |
Any grade (1–5) | 17 (36) | 26 (25) | 0.1490 |
Grade 3–5 | 3 (6) | 7 (7) | 0.9480 |
Tocilizumab use, n (%) | 32 (68) | 62 (59) | 0.2891 |
Steroids use, n (%) | 19 (40) | 25 (24) | 0.0368 |
Anakinra use, n (%) | 10 (21) | 3 (3) | 0.0002 |
Infections (all grade), n (%) | 20 (43) | 32 (30) | 0.1469 |
G-CSF use, n (%) | 25 (53) | 54 (51) | 0.8407 |
TPO agonist use, n (%) | 18 (38) | 16 (15) | 0.0208 |
Stem cell boost, n (%) | 11 (23) | 4 (4) | 0.0002 |
Hematologic toxicity at Day 30 post CAR T infusion | N = 42 | N = 105 | |
Neutropenia at day 30, n (%) | |||
Any grade (1–5) | 31 (74) | 71 (68) | 0.4619 |
Grade 3–5 | 20 (48) | 38 (36) | 0.2003 |
Anemia at Day 30, n (%) | |||
Any grade (1–5) | 37 (88) | 81 (77) | 0.1317 |
Grade 3–5 | 9 (21) | 16 (15) | 0.3332 |
Thrombocytopenia at Day 30, n (%) | |||
Any grade (1–5) | 40 (95) | 78 (74) | 0.0006 |
Grade 3–5 | 26 (62) | 40 (38) | 0.0087 |
Hematologic Toxicity at Day 90 post CAR T infusion | N = 30 | N = 96 | |
Neutropenia at Day 90 | |||
Any grade (1–5) | 13 (43) | 31 (32) | 0.2681 |
Grade 3–5 | 3 (10) | 14 (15) | 0.5213 |
Anemia at Day 90 | |||
Any grade (1–5) | 20 (67) | 46 (48) | 0.0727 |
Grade 3–5 | 3 (30) | 5 (5) | 0.3475 |
Thrombocytopenia at Day 90 | |||
Any grade (1–5) | 20 (67) | 45 (47) | 0.0583 |
Grade 3–5 | 5 (17) | 12 (13) | 0.5598 |
